JP7596260B2 - 可溶性ｂｃｍａに対する抗体 - Google Patents

可溶性ｂｃｍａに対する抗体 Download PDF

Info

Publication number
JP7596260B2
JP7596260B2 JP2021516763A JP2021516763A JP7596260B2 JP 7596260 B2 JP7596260 B2 JP 7596260B2 JP 2021516763 A JP2021516763 A JP 2021516763A JP 2021516763 A JP2021516763 A JP 2021516763A JP 7596260 B2 JP7596260 B2 JP 7596260B2
Authority
JP
Japan
Prior art keywords
sbcma
antibody
seq
monoclonal antibody
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021516763A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501389A5 (enExample
JP2022501389A (ja
Inventor
キエルツジェフスカ，アグニェシュカ
チャン，ブライアン
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2022501389A publication Critical patent/JP2022501389A/ja
Publication of JP2022501389A5 publication Critical patent/JP2022501389A5/ja
Priority to JP2024100215A priority Critical patent/JP2024147571A/ja
Application granted granted Critical
Publication of JP7596260B2 publication Critical patent/JP7596260B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021516763A 2018-09-28 2019-09-27 可溶性ｂｃｍａに対する抗体 Active JP7596260B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024100215A JP2024147571A (ja) 2018-09-28 2024-06-21 可溶性ｂｃｍａに対する抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862738997P 2018-09-28 2018-09-28
US62/738,997 2018-09-28
PCT/US2019/053433 WO2020069303A1 (en) 2018-09-28 2019-09-27 Antibodies against soluble bcma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024100215A Division JP2024147571A (ja) 2018-09-28 2024-06-21 可溶性ｂｃｍａに対する抗体

Publications (3)

Publication Number Publication Date
JP2022501389A JP2022501389A (ja) 2022-01-06
JP2022501389A5 JP2022501389A5 (enExample) 2022-10-04
JP7596260B2 true JP7596260B2 (ja) 2024-12-09

Family

ID=68296657

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021516763A Active JP7596260B2 (ja) 2018-09-28 2019-09-27 可溶性ｂｃｍａに対する抗体
JP2024100215A Withdrawn JP2024147571A (ja) 2018-09-28 2024-06-21 可溶性ｂｃｍａに対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024100215A Withdrawn JP2024147571A (ja) 2018-09-28 2024-06-21 可溶性ｂｃｍａに対する抗体

Country Status (11)

Country Link
US (1) US11505614B2 (enExample)
EP (1) EP3856781A1 (enExample)
JP (2) JP7596260B2 (enExample)
KR (1) KR102994831B1 (enExample)
CN (1) CN112703204B (enExample)
AR (1) AR116548A1 (enExample)
BR (1) BR112021005669A2 (enExample)
MA (1) MA53732A (enExample)
TW (1) TW202028239A (enExample)
UY (1) UY38393A (enExample)
WO (1) WO2020069303A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE068401T2 (hu) * 2019-11-11 2024-12-28 Amgen Res Munich Gmbh A BCMA elleni hatóanyagok adagolási rendje
EP4611774A2 (en) * 2022-11-04 2025-09-10 MiNK Therapeutics, Inc. B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof
WO2024168192A1 (en) * 2023-02-10 2024-08-15 Celgene Corporation Assessment of bcma in biological samples
CN119529089B (zh) * 2023-08-28 2025-11-18 菲鹏生物股份有限公司 一种抗生长刺激表达基因2蛋白的抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018050627A (ja) 2011-11-15 2018-04-05 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH Ｂｃｍａおよびｃｄ３に対する結合分子
JP2018087190A (ja) 2011-05-27 2018-06-07 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）結合タンパク質

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1985A (en) 1841-02-18 Charles m
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
DK0575319T3 (da) 1991-03-11 2000-07-10 Univ Georgia Res Found Kloning og ekspression af Renilla-luciferase
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
CA2169298A1 (en) 1993-09-10 1995-03-16 Martin Chalfie Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
ATE290205T1 (de) 1996-12-12 2005-03-15 Prolume Ltd Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen
AU765703B2 (en) 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
ES2207278T3 (es) 1998-07-28 2004-05-16 Micromet Ag Heterominicuerpos.
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
WO2014151910A1 (en) 2013-03-15 2014-09-25 Amgen Inc. Heterodimeric bispecific antibodies
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
WO2015048272A1 (en) 2013-09-25 2015-04-02 Amgen Inc. V-c-fc-v-c antibody
EP3029068A1 (en) * 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
JP6901493B2 (ja) * 2015-11-13 2021-07-14 アメリカ合衆国 抗ｂｃｍａポリペプチド及びタンパク質
DK3402515T3 (da) * 2016-01-12 2021-11-15 Oncotracker Inc Forbedrede fremgangsmåder til monitorering af et individs immunstatus
UA126657C2 (uk) 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Ґмбг ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018087190A (ja) 2011-05-27 2018-06-07 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）結合タンパク質
JP2018050627A (ja) 2011-11-15 2018-04-05 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH Ｂｃｍａおよびｃｄ３に対する結合分子

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Haematologica，2017年，Volume 102, No.4，pp.785-795

Also Published As

Publication number Publication date
JP2024147571A (ja) 2024-10-16
KR102994831B1 (ko) 2026-07-23
WO2020069303A1 (en) 2020-04-02
US20200102398A1 (en) 2020-04-02
AR116548A1 (es) 2021-05-19
CN112703204A (zh) 2021-04-23
JP2022501389A (ja) 2022-01-06
CN112703204B (zh) 2024-10-01
UY38393A (es) 2020-03-31
KR20210068408A (ko) 2021-06-09
EP3856781A1 (en) 2021-08-04
BR112021005669A2 (pt) 2021-06-22
MA53732A (fr) 2022-01-05
US11505614B2 (en) 2022-11-22
TW202028239A (zh) 2020-08-01

Similar Documents

Publication Publication Date Title
JP7623006B2 (ja) 特異的結合剤により認識されるエピトープタグ
JP2024147571A (ja) 可溶性ｂｃｍａに対する抗体
US9458244B2 (en) Single chain multivalent binding protein compositions and methods
JP7750852B2 (ja) ムチン１７に対する抗体及びその使用
US12221484B2 (en) Anti-NMDA receptor antibodies and methods of use
US20170320966A1 (en) Humanized monoclonal antibody and uses thereof
EP3533459A1 (en) Anti-pla2-gib antibodies and the uses thereof
WO2019156223A1 (ja) チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
CN115960219B (zh) 抗SARS-CoV-2刺突蛋白S1的单克隆抗体及其应用
CN113366021A (zh) 糖基化Apo J特异性抗体及其用途
TW202216758A (zh) 抗人類免疫缺陷病毒－１抗體、包含其的細胞、核酸、組合物及套組
KR20250154412A (ko) 항원 결합 분자 및 사용 방법
WO2019084427A1 (en) T-LYMPHOCYTE RECEPTOR ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF
TW201739769A (zh) 人源化之單株抗體及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220926

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240621

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241017

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241029

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241127

R150 Certificate of patent or registration of utility model

Ref document number: 7596260

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150